Enhancing case ascertainment of Parkinson's disease using Medicare claims data in a population-based cohort: The Cardiovascular Health Study

Pharmacoepidemiology and Drug Safety

Volumn 23, Issue 2, 2014, Pages 119-127

  Ton, Thanh G N ^a   Biggs, Mary Lou ^b   Comer, Diane ^c   Curtis, Lesley ^d   Hu, Shu Ching ^a   Thacker, Evan L ^e   Searles Nielsen, Susan ^f   Delaney, Joseph A ^b   Landsittel, Douglas ^c   Longstreth, William T ^a,b   Checkoway, Harvey ^f   Jain, Samay ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^e BRIGHAM YOUNG UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cardiovascular disease; Cardiovascular health study; Epidemiology; ICD 9; Medical records; Parkinson's disease; Pharmacoepidemiology

Indexed keywords

ANTIPARKINSON AGENT;

AFRICAN AMERICAN; AGE; AGED; ARTICLE; CASE ASCERTAINMENT; CAUSE OF DEATH; CLASSIFICATION ALGORITHM; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; EDUCATION; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; ICD-9; INCIDENCE; MALE; MEDICAL FEE; MEDICAL RECORD REVIEW; MEDICARE; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; SELF REPORT; SEX; SMOKING;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR HEALTH STUDY; EPIDEMIOLOGY; ICD-9; MEDICAL RECORDS; PARKINSON'S DISEASE; PHARMACOEPIDEMIOLOGY;

AGED; AGED, 80 AND OVER; ALGORITHMS; ANTIPARKINSON AGENTS; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; HOSPITALIZATION; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MEDICARE; PARKINSON DISEASE; PREVALENCE; PROSPECTIVE STUDIES; SMOKING; TIME FACTORS; UNITED STATES;

EID: 84892861290     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3552     Document Type: Article

References (32)

1. Ascherio A, Chen H, Schwarzschild MA, Zhang SM, Colditz GA, Speizer FE. Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. Neurology 2003; 60: 790-795.
2. Chen H, Schernhammer E, Schwarzschild MA, Ascherio A. A prospective study of night shift work, sleep duration, and risk of Parkinson's disease. Am J Epidemiol 2006; 163: 726-730.
3. Chen H, Zhang SM, Hernan MA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 2003; 60: 1059-1064.
4. Gao X, Chen H, Schwarzschild MA, Ascherio A. Use of ibuprofen and risk of Parkinson disease. Neurology 2011; 76: 863-869.
5. Gao X, Simon KC, Schwarzschild MA, Ascherio A. Prospective study of statin use and risk of Parkinson disease. Arch Neurol 2012; 69: 380-384.
6. Thacker EL, O'Reilly EJ, Weisskopf MG, et al. Temporal relationship between cigarette smoking and risk of Parkinson disease. Neurology 2007; 68: 764-768.
7. Zhang SM, Hernan MA, Chen H, Spiegelman D, Willett WC, Ascherio A. Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology 2002; 59: 1161-1169.
8. Simon KC, Chen H, Schwarzschild M, Ascherio A. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 2007; 69: 1688-1695.
9. Hernan MA, Chen H, Schwarzschild MA, Ascherio A. Alcohol consumption and the incidence of Parkinson's disease. Ann Neurol 2003; 54: 170-175.
10. Palacios N, Gao X, McCullough ML, et al. Obesity, diabetes, and risk of Parkinson's disease. Mov Disord 2011; 26: 2253-2259.
11. Palacios N, Gao X, O'Reilly E, et al. Alcohol and risk of Parkinson's disease in a large, prospective cohort of men and women. Mov Disord 2012; 27: 980-987.
12. Dawber TR, Meadors GF, Moore FE, Jr. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health Nations Health 1951; 41: 279-281.
13. ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol 1989; 129: 687-702.
14. Bild DE, Bluemke DA, Burke GL, et al. Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol 2002; 156: 871-881.
15. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1991; 1: 263-276.
16. Ton TG, Jain S, Boudreau R, et al. Post hoc Parkinson's disease: identifying an uncommon disease in the Cardiovascular Health Study. Neuroepidemiology 2010; 35: 241-249.
17. Rothman KJ, Greenland S, Lash TL. Modern epidemiology (3rd edn), Wolters Kluwer Health/Lippincott Williams & Wilkins: Philadelphia; 2008.
18. Medicare: A Primer. Menlo Park: The Henry J. Kaiser Family Foundation; 2010 Contract No.: Document Number|.
19. Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 2002; 52: 276-284.
20. Jorm LR, Shepherd LC, Rogers KD, Blyth FM. Smoking and use of primary care services: findings from a population-based cohort study linked with administrative claims data. BMC health services res 2012; 12: 263.
21. Dorn HF. Tobacco consumption and mortality from cancer and other diseases. Public Health Rep 1959; 74: 581-593.
22. Ritz B, Ascherio A, Checkoway H, et al. Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol 2007; 64: 990-997.
23. Chen H, Huang X, Guo X, et al. Smoking duration, intensity, and risk of Parkinson disease. Neurology 2010; 74: 878-884.
24. Fall PA, Axelson O, Fredriksson M, et al. Age-standardized incidence and prevalence of Parkinson's disease in a Swedish community. J Clin Epidemiol 1996; 49: 637-641.
25. von Campenhausen S, Bornschein B, Wick R, et al. Prevalence and incidence of Parkinson's disease in Europe. Eur Neuropsychopharmacol 2005; 15: 473-490.
26. Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003; 157: 1015-1022.
27. Mayeux R, Marder K, Cote LJ, et al. The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993. Am J Epidemiol 1995; 142: 820-827.
28. von Campenhausen S, Bornschein B, Wick R, et al. Prevalence and incidence of Parkinson's disease in Europe. European neuropsychopharmacology: J ECNP 2005; 15: 473-490.
29. Twelves D, Perkins KS, Counsell C. Systematic review of incidence studies of Parkinson's disease. Mov Disord 2003; 18: 19-31.
30. National Collaborating Centre for Chronic Conditions (UK). Parkinson's Disease: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care. : London: Royal College of Physicians (UK); 2006. (NICE Clinical Guidelines, No. 25.) 5, Diagnosing Parkinson's disease. Available from: http://www.ncbi.nlm.nih.gov/books/NBK48502/.
31. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Medical care 2002; 40: IV-3-18.
32. DiMartino LD, Hammill BG, Curtis LH, et al. External validity of the cardiovascular health study: a comparison with the Medicare population. Medical care 2009; 47: 916-923.